Grants for glaucoma research. 来自 EBSCO 喜欢 0 阅读量: 23 摘要: The article offers information on the research grant of the American Health Assistance Foundation that furnishes grant funding for degenerative disease research, under the National Glaucoma Research program, in the U.S....
Reports on several health research grants in the U.S. Clinical trials on the safety and efficacy of products for rare diseases and conditions; Cooperative agreement applications to support faculty positions in medical schools specializing in training related to sexually transmitted disease prevention and...
Sarepta provides grant funding for programs that enable education, address unmet needs of rare disease patients, promote the highest standards of care, raise awareness of ongoing research, or focus on other critical community initiatives. Requests will be considered across the spectrum of neuromuscular...
Earlier this year, FDA granted REVASCOR both Rare Pediatric Disease Designation (RPDD) and Orphan-Drug Designation (ODD) for treatment of children with HLHS. RPDD demonstrates that the disease is serious or life-threatening and the manifestations primarily affect individuals aged from birt...
Three sites in the Friedreich's Ataxia Research Alliance (FARA) Collaborative Clinical Research Network are conducting clinical trials with EPI-743. Orphan Drug Designation Orphan drug status confers incentives to drug companies working on pharmaceutical interventions for rare diseases and conditions. ...
The FDA granted this application Fast Track and Priority Review designations. Vyondys 53 also received Orphan Drug designation, which provides incentives to assist and encourage the development of drugs for rare diseases. In addition, the manufacturer received a rare ...
Mabwell has been granted Orphan Drug Designation (ODD) by the U.S. Food and Drug Administration (FDA), for the treatment of esophageal cancer.
PTC provides support in the form of a medical research grant. All IIS requests will be submitted to the PTC review committee comprised of medical and scientific personnel for consideration. Independent requests must have clear objectives and be in alignment with areas of interest to PTC. The ...
Food and Drug Administration has accepted and granted Priority Review for the company’s Biologics License Application for zolbetuximab, a first-in-class investigational Claudin 18.2 -targeted monoclonal antibody, for first-line treatment of patients with locally advanced u...
For more information about BIOM Pharmaceutical Corporation and its groundbreaking work in rare disease therapeutics, please visithttps://www.biompharma.com/. About BIOM Pharmaceutical Corporation: Biom Pharmaceutical is committed ...